Low cabotegravir trough concentrations without oral lead-in in patients with HIV-1 switching to long-acting cabotegravir and rilpivirine

AIDS. 2024 Jul 1;38(8):1267-1269. doi: 10.1097/QAD.0000000000003887. Epub 2024 May 30.

Abstract

In a cohort of 72 consecutive virologically-suppressed patients with HIV-1 switching to long-acting cabotegravir and rilpivirine, we observed low cabotegravir trough concentrations 1 and 3 months after the first injection, with a significant association with no oral lead-in at 1 month [odds ratio (OR) = 6.3 [95% confidence interval (CI) 1.7-29.5], P = 0.01] and three months (OR = 5.6 [95% CI 1.3-29.7], P = 0.03), and with high BMI at 1 month (OR = 1.3 [95% CI 1.1-1.6], P = 0.007).

MeSH terms

  • Administration, Oral
  • Adult
  • Anti-HIV Agents* / administration & dosage
  • Anti-HIV Agents* / pharmacokinetics
  • Anti-HIV Agents* / therapeutic use
  • Diketopiperazines
  • Drug Substitution
  • Female
  • HIV Infections* / drug therapy
  • HIV-1* / isolation & purification
  • Humans
  • Male
  • Middle Aged
  • Plasma / chemistry
  • Pyridones* / administration & dosage
  • Rilpivirine* / administration & dosage
  • Rilpivirine* / pharmacokinetics
  • Rilpivirine* / therapeutic use

Substances

  • cabotegravir
  • Pyridones
  • Rilpivirine
  • Anti-HIV Agents
  • Diketopiperazines